Biotech Acquisition Company Class A Ordinary Shares
BIOT
BIOT was delisted on the 2nd of February, 2023.
69 hedge funds and large institutions have $226M invested in Biotech Acquisition Company Class A Ordinary Shares in 2022 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 15 increasing their positions, 9 reducing their positions, and 7 closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 9
29% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 7
3% more funds holding
Funds holding: 67 → 69 (+2)
4% more capital invested
Capital invested by funds: $218M → $226M (+$7.64M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCL
Glazer Capital LLC
New York
|
+$16.3M |
| 2 |
HSBC Holdings
London,
United Kingdom
|
+$6.31M |
| 3 |
MSU
Mizuho Securities USA
New York
|
+$4.4M |
| 4 |
Millennium Management
New York
|
+$2.45M |
| 5 |
WRBC
W.R. Berkley Corp
Greenwich,
Connecticut
|
+$2.36M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$18M |
| 2 |
LA
Linden Advisors
New York
|
-$6.31M |
| 3 |
RL
RPO LLC
Stamford,
Connecticut
|
-$2.47M |
| 4 |
WAM
Weiss Asset Management
Boston,
Massachusetts
|
-$2.33M |
| 5 |
Goldman Sachs
New York
|
-$2.3M |
BIOT Hedge Fund Activity: Q3 2022 in Review
69 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Biotech Acquisition Company Class A Ordinary Shares (BIOT) for Q3 2022, worth a combined $226M — up 3.5% from $218M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new BIOT positions and 7 closed out — a net gain of 2 holders — while 15 added to existing stakes and 9 trimmed.
The largest buyer was Glazer Capital LLC, adding an estimated $16.3M. The largest seller was JP Morgan Chase, cutting an estimated $18M.
- 69 institutional investors held Biotech Acquisition Company Class A Ordinary Shares (BIOT) as of Q3 2022, up from 67 in Q2 2022.
- Funds reported $226M of Biotech Acquisition Company Class A Ordinary Shares stock for Q3 2022, up 3.5% quarter-over-quarter.
- 9 funds opened new Biotech Acquisition Company Class A Ordinary Shares positions in Q3 2022 and 7 closed out, a net change of +2 holders.
- The largest Biotech Acquisition Company Class A Ordinary Shares buyer in Q3 2022 was Glazer Capital LLC, an estimated $16.3M added.
- The largest Biotech Acquisition Company Class A Ordinary Shares seller in Q3 2022 was JP Morgan Chase, an estimated $18M sold.
Based on aggregated 13F filings for Q3 2022.